Dymista® delivers relief from a range of nasal and ocular symptoms of allergic rhinitis.1-4 Watch how the two individual components of Dymista®125/50, azelastine (anti-histamine) and fluticasone propionate (anti-inflammatory corticosteroid) act to disrupt allergic responses and provide broader pathophysiological coverage than some other allergic rhinitis treatments available.5,6
PBS Information: This product is not listed on the PBS.
PLEASE REVIEW PRODUCT INFORMATION AVAILABLE HERE, BEFORE PRESCRIBING.
References: 1. Dymista® 125/50 Approved Product Information. 2. Meltzer E, et al. Int Arch Allergy Immunol. 2013; 161(4):369–77. 3. Carr W, et al. J Allergy Clin Immunol 2012;129(5):1282-9. 4. Hampel F, et al. Ann Allergy Asthma Immunol 2010; 105(2):168–73. 5. Bjermer L, et al. Allergy Asthma Clin Immunol. 2019;15:24. 6. Montelukast Mylan Approved Product Information 2019.
Want more information on Dymista® or other Viatris products and services?
Privacy Notice | Terms of Use | Cookie Notice | Contact Us
Dymista® is a Viatris registered trademark. Copyright © 2022 Viatris Inc. All rights reserved. Viatris Pty Ltd. ABN 29 601 608 771. Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, Australia. Ph: 1800 314 527. DYM-2022-0382. May 2022.
The Viatris Privacy Notice describes our collection, use, disclosure, and retention of Personal Data. The Notice also explains the ways in which you may, under applicable laws, be able to control our processing of your Personal Data and exercise other rights.
